Ligand free FeSn2 alloy nanoparticles for safe T2-weighted MR imaging of in vivo lung tumors

Thangudu, Suresh; Lin, Wei-Che; Lee, Chin‐Lai; Liao, Min-Chiao; Yu, Chia‐Li; Wang, Yuming; Su, Chia‐Hao

doi:10.1039/d2bm01517j

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results reveal the significant enhancement of absorption intensity at 340 nm wavelength by increasing the mGEF concentration on NPs ( Supplementary Figure S3 ). In addition, Iron-based NPs are proven T2-weighed MRI contrast agents and display excellent MR contrast abilities both in vitro and in vivo ( Shen et al, 2017 ; Thangudu et al, 2022b ; Thangudu et al, 2023 ). To verify the contrast enhancement efficiency of present synthesized-Fe 3 O 4 NPs, T2-weighted MRI analysis was performed with a 7.0 T MRI scanner.…”

Section: Resultsmentioning

confidence: 99%

Modified gefitinib conjugated Fe3O4 NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer

Thangudu,

Tsai,

Lin

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

Gefitinib (GEF) is an FDA-approved anti-cancer drug for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC). However, the efficacy of anticancer drugs is limited due to their non-specificity, lower accumulation at target sites, and systemic toxicity. Herein, we successfully synthesized a modified GEF (mGEF) drug and conjugated to Iron oxide nanoparticles (Fe3O4 NPs) for the treatment of NSCLC via magnetic resonance (MR) image-guided drug delivery. A traditional EDC coupling pathway uses mGEF to directly conjugate to Fe3O4 NPs to overcom the drug leakage issues. As a result, we found in vitro drug delivery on mGEF- Fe3O4 NPs exhibits excellent anticancer effects towards the PC9 cells selectively, with an estimated IC 50 value of 2.0 μM. Additionally, in vivo MRI and PET results demonstrate that the NPs could accumulate in tumor-specific regions with localized cell growth inhibition. Results also revealed that outer tumor region exhibiting a stronger contrast than the tinner tumor region which may due necrosis in inner tumor region. In vivo biodistribution further confirms Fe3O4 NPs are more biocompatible and are excreated after the treatment. Overall, we believe that this current strategy of drug modification combined with chemical conjugation on magnetic NPs will lead to improved cancer chemotherapy as well as understanding the tumor microenvironments for better therapeutic outcomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Modified gefitinib conjugated Fe3O4 NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer

Thangudu,

Tsai,

Lin

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

Ligand free FeSn₂ alloy nanoparticles for safe T₂-weighted MR imaging of in vivo lung tumors

Abstract: Biosafety is a critical issue for the successful translocation of nanomaterial-based therapeutic/diagnostic agents from bench to bedside. For instance, after the withdrawal of clinically approved magnetic Resonance Imaging (MRI) contrast...

Cited by 1 publication

References 50 publications

Modified gefitinib conjugated Fe3O4 NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer

Modified gefitinib conjugated Fe3O4 NPs for improved delivery of chemo drugs following an image-guided mechanistic study of inner vs. outer tumor uptake for the treatment of non-small cell lung cancer

Contact Info

Product

Resources

About